Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Follicular B2 Cell Activation and Class Switch Recombination Depend on Autocrine C3ar1/C5ar1 Signaling in B2 Cells.

Paiano J, Harland M, Strainic MG, Nedrud J, Hussain W, Medof ME.

J Immunol. 2019 Jul 15;203(2):379-388. doi: 10.4049/jimmunol.1900276. Epub 2019 Jun 19.

PMID:
31217324
2.

CD55 Is Essential for CD103+ Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity.

Strainic MG, Liu J, An F, Bailey E, Esposito A, Hamann J, Heeger PS, Medof ME.

Am J Pathol. 2019 Jul;189(7):1386-1401. doi: 10.1016/j.ajpath.2019.04.008. Epub 2019 May 17.

PMID:
31103439
3.

VEGFR2 survival and mitotic signaling depends on joint activation of associated C3ar1/C5ar1 and IL-6R-gp130.

Hwang MS, Strainic MG, Pohlmann E, Kim H, Pluskota E, Ramirez-Bergeron DL, Plow EF, Medof ME.

J Cell Sci. 2019 Mar 28;132(6). pii: jcs219352. doi: 10.1242/jcs.219352.

PMID:
30765465
4.

Anaphylatoxin Receptors C3aR and C5aR1 Are Important Factors That Influence the Impact of Ethanol on the Adipose Secretome.

McCullough RL, McMullen MR, Poulsen KL, Kim A, Medof ME, Nagy LE.

Front Immunol. 2018 Sep 20;9:2133. doi: 10.3389/fimmu.2018.02133. eCollection 2018.

5.

C5aR1 regulates migration of suppressive myeloid cells required for costimulatory blockade-induced murine allograft survival.

Llaudo I, Fribourg M, Medof ME, Conde P, Ochando J, Heeger PS.

Am J Transplant. 2019 Mar;19(3):633-645. doi: 10.1111/ajt.15072. Epub 2018 Sep 17.

PMID:
30106232
6.

T Cell Expression of C5a Receptor 2 Augments Murine Regulatory T Cell (TREG) Generation and TREG-Dependent Cardiac Allograft Survival.

A Verghese D, Demir M, Chun N, Fribourg M, Cravedi P, Llaudo I, Woodruff TM, Yadav P, Lira SA, Medof ME, Heeger PS.

J Immunol. 2018 Mar 15;200(6):2186-2198. doi: 10.4049/jimmunol.1701638. Epub 2018 Feb 7.

7.

DAF in diabetic patients is subject to glycation/inactivation at its active site residues.

Flückiger R, Cocuzzi E, Nagaraj RH, Shoham M, Kern TS, Medof ME.

Mol Immunol. 2018 Jan;93:246-252. doi: 10.1016/j.molimm.2017.06.036. Epub 2017 Sep 5.

8.

TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement.

Sheen JH, Strainic MG, Liu J, Zhang W, Yi Z, Medof ME, Heeger PS.

J Immunol. 2017 Jul 1;199(1):278-291. doi: 10.4049/jimmunol.1700339. Epub 2017 May 24.

9.

Differential contribution of complement receptor C5aR in myeloid and non-myeloid cells in chronic ethanol-induced liver injury in mice.

McCullough RL, McMullen MR, Das D, Roychowdhury S, Strainic MG, Medof ME, Nagy LE.

Mol Immunol. 2016 Jul;75:122-32. doi: 10.1016/j.molimm.2016.05.006. Epub 2016 Jun 6.

10.

Shear stress-dependent downregulation of the adhesion-G protein-coupled receptor CD97 on circulating leukocytes upon contact with its ligand CD55.

Karpus ON, Veninga H, Hoek RM, Flierman D, van Buul JD, Vandenakker CC, vanBavel E, Medof ME, van Lier RA, Reedquist KA, Hamann J.

J Immunol. 2013 Apr 1;190(7):3740-8. doi: 10.4049/jimmunol.1202192. Epub 2013 Feb 27.

11.

Absence of signaling into CD4⁺ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3⁺ regulatory T cells.

Strainic MG, Shevach EM, An F, Lin F, Medof ME.

Nat Immunol. 2013 Feb;14(2):162-71. doi: 10.1038/ni.2499. Epub 2012 Dec 23.

12.

Antigen-presenting cell-derived complement modulates graft-versus-host disease.

Kwan WH, Hashimoto D, Paz-Artal E, Ostrow K, Greter M, Raedler H, Medof ME, Merad M, Heeger PS.

J Clin Invest. 2012 Jun;122(6):2234-8. doi: 10.1172/JCI61019. Epub 2012 May 15.

13.

A novel role for CD55 in granulocyte homeostasis and anti-bacterial host defense.

Veninga H, Hoek RM, de Vos AF, de Bruin AM, An FQ, van der Poll T, van Lier RA, Medof ME, Hamann J.

PLoS One. 2011;6(10):e24431. doi: 10.1371/journal.pone.0024431. Epub 2011 Oct 3.

14.

Complement regulates CD4 T-cell help to CD8 T cells required for murine allograft rejection.

Vieyra M, Leisman S, Raedler H, Kwan WH, Yang M, Strainic MG, Medof ME, Heeger PS.

Am J Pathol. 2011 Aug;179(2):766-74. doi: 10.1016/j.ajpath.2011.04.038. Epub 2011 Jun 23.

15.

Interaction of decay-accelerating factor with echovirus 7.

Plevka P, Hafenstein S, Harris KG, Cifuente JO, Zhang Y, Bowman VD, Chipman PR, Bator CM, Lin F, Medof ME, Rossmann MG.

J Virol. 2010 Dec;84(24):12665-74. doi: 10.1128/JVI.00837-10. Epub 2010 Sep 29.

16.

Immune cell-derived c3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin.

Lin M, Yin N, Murphy B, Medof ME, Segerer S, Heeger PS, Schröppel B.

Diabetes. 2010 Sep;59(9):2247-52. doi: 10.2337/db10-0044. Epub 2010 Jun 28.

17.

The intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injury.

Sakuma M, Morooka T, Wang Y, Shi C, Croce K, Gao H, Strainic M, Medof ME, Simon DI.

Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1196-202. doi: 10.1161/ATVBAHA.110.205559. Epub 2010 Mar 18.

18.

Deletion of either CD55 or CD97 ameliorates arthritis in mouse models.

Hoek RM, de Launay D, Kop EN, Yilmaz-Elis AS, Lin F, Reedquist KA, Verbeek JS, Medof ME, Tak PP, Hamann J.

Arthritis Rheum. 2010 Apr;62(4):1036-42. doi: 10.1002/art.27347.

19.

Decay accelerating factor is essential for successful corneal engraftment.

Esposito A, Suedekum B, Liu J, An F, Lass J, Strainic MG, Lin F, Heeger P, Medof ME.

Am J Transplant. 2010 Mar;10(3):527-34. doi: 10.1111/j.1600-6143.2009.02961.x. Epub 2010 Jan 5.

20.

Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation.

Raedler H, Yang M, Lalli PN, Medof ME, Heeger PS.

Am J Transplant. 2009 Aug;9(8):1784-95. doi: 10.1111/j.1600-6143.2009.02723.x. Epub 2009 Jun 26.

21.

Locally produced and activated complement as a mediator of alloreactive T cells.

Lalli PN, Zhou W, Sacks S, Medof ME, Heeger PS.

Front Biosci (Schol Ed). 2009 Jun 1;1:117-24. Review.

PMID:
19482687
22.

An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice.

Roychowdhury S, McMullen MR, Pritchard MT, Hise AG, van Rooijen N, Medof ME, Stavitsky AB, Nagy LE.

Hepatology. 2009 Apr;49(4):1326-34. doi: 10.1002/hep.22776.

23.

Role of complement in ethanol-induced liver injury.

Pritchard MT, McMullen MR, Medof ME, Stavitsky A, Nagy LE.

Adv Exp Med Biol. 2008;632:175-86. Review.

PMID:
19025122
24.

Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection.

Pavlov V, Raedler H, Yuan S, Leisman S, Kwan WH, Lalli PN, Medof ME, Heeger PS.

J Immunol. 2008 Oct 1;181(7):4580-9.

25.

Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.

Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS.

Blood. 2008 Sep 1;112(5):1759-66. doi: 10.1182/blood-2008-04-151068. Epub 2008 Jun 20.

26.

IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production.

Liu J, Lin F, Strainic MG, An F, Miller RH, Altuntas CZ, Heeger PS, Tuohy VK, Medof ME.

J Immunol. 2008 May 1;180(9):5882-9.

27.

Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells.

Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS, Dubyak GR, Heeger PS, Medof ME.

Immunity. 2008 Mar;28(3):425-35. doi: 10.1016/j.immuni.2008.02.001. Epub 2008 Mar 6.

28.

Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis.

Zhou Y, Gong B, Lin F, Rother RP, Medof ME, Kaminski HJ.

J Immunol. 2007 Dec 15;179(12):8562-7.

29.
30.

Interaction of decay-accelerating factor with coxsackievirus B3.

Hafenstein S, Bowman VD, Chipman PR, Bator Kelly CM, Lin F, Medof ME, Rossmann MG.

J Virol. 2007 Dec;81(23):12927-35. Epub 2007 Sep 5.

31.

Graft-derived complement as a mediator of transplant injury.

Zhou W, Medof ME, Heeger PS, Sacks S.

Curr Opin Immunol. 2007 Oct;19(5):569-76. Epub 2007 Aug 30. Review. No abstract available.

PMID:
17764920
32.

Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases.

Kuttner-Kondo L, Hourcade DE, Anderson VE, Muqim N, Mitchell L, Soares DC, Barlow PN, Medof ME.

J Biol Chem. 2007 Jun 22;282(25):18552-62. Epub 2007 Mar 29.

33.

Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.

Kaminski HJ, Kusner LL, Richmonds C, Medof ME, Lin F.

Exp Neurol. 2006 Dec;202(2):287-93. Epub 2006 Jul 20.

PMID:
16859686
34.

The role of decay-accelerating factor as a receptor for Helicobacter pylori and a mediator of gastric inflammation.

O'Brien DP, Israel DA, Krishna U, Romero-Gallo J, Nedrud J, Medof ME, Lin F, Redline R, Lublin DM, Nowicki BJ, Franco AT, Ogden S, Williams AD, Polk DB, Peek RM Jr.

J Biol Chem. 2006 May 12;281(19):13317-23. Epub 2006 Mar 16.

35.

Decay-accelerating factor modulates induction of T cell immunity.

Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, Xu Y, Medof ME.

J Exp Med. 2005 May 16;201(10):1523-30. Epub 2005 May 9.

36.

Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.

Kaminski HJ, Li Z, Richmonds C, Lin F, Medof ME.

Exp Neurol. 2004 Oct;189(2):333-42.

PMID:
15380483
37.

An atomic resolution model for assembly, architecture, and function of the Dr adhesins.

Anderson KL, Billington J, Pettigrew D, Cota E, Simpson P, Roversi P, Chen HA, Urvil P, du Merle L, Barlow PN, Medof ME, Smith RA, Nowicki B, Le Bouguénec C, Lea SM, Matthews S.

Mol Cell. 2004 Aug 27;15(4):647-57.

38.
39.

Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis.

Lin F, Salant DJ, Meyerson H, Emancipator S, Morgan BP, Medof ME.

J Immunol. 2004 Feb 15;172(4):2636-42.

40.

A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases.

Kuttner-Kondo LA, Dybvig MP, Mitchell LM, Muqim N, Atkinson JP, Medof ME, Hourcade DE.

J Biol Chem. 2003 Dec 26;278(52):52386-91. Epub 2003 Oct 15.

41.

Solution structure of a functionally active fragment of decay-accelerating factor.

Uhrinova S, Lin F, Ball G, Bromek K, Uhrin D, Medof ME, Barlow PN.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4718-23. Epub 2003 Apr 2.

42.

On the same cell type GPI-anchored normal cellular prion and DAF protein exhibit different biological properties.

Li R, Liu T, Yoshihiro F, Tary-Lehmann M, Obrenovich M, Kuekrek H, Kang SC, Pan T, Wong BS, Medof ME, Sy MS.

Biochem Biophys Res Commun. 2003 Apr 4;303(2):446-51.

PMID:
12659837
43.

Proprotein interaction with the GPI transamidase.

Chen R, Anderson V, Hiroi Y, Medof ME.

J Cell Biochem. 2003 Apr 1;88(5):1025-37.

PMID:
12616539
44.
45.

Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.

Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME.

J Clin Invest. 2002 Nov;110(9):1269-74.

46.

Resonance assignments of the central complement control protein module pair of human decay accelerating factor.

Uhrínová S, Lin F, Uhrín D, Medof ME, Barlow PN.

J Biomol NMR. 2002 Jun;23(2):167-8. No abstract available.

PMID:
12153048
47.

Structure of decay-accelerating factor bound to echovirus 7: a virus-receptor complex.

He Y, Lin F, Chipman PR, Bator CM, Baker TS, Shoham M, Kuhn RJ, Medof ME, Rossmann MG.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10325-9. Epub 2002 Jul 15.

48.

Letter to the Editor: Resonance assignments of the central complement control protein module pair of human decay accelerating factor.

Uhrínová S, Lin F, Uhrín du U, Medof ME, Barlow PN.

J Biomol NMR. 2002 Jun;23(2):167-8. doi: 10.1023/A:1016362923187. No abstract available.

PMID:
20859790
49.

Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis.

Lin F, Emancipator SN, Salant DJ, Medof ME.

Lab Invest. 2002 May;82(5):563-9.

PMID:
12003997
50.

Blockage of complement regulators in the conjunctiva and within the eye leads to massive inflammation and iritis.

Bardenstein DS, Cheyer CJ, Lee C, Cocuzzi E, Mizuno M, Okada N, Medof ME.

Immunology. 2001 Dec;104(4):423-30.

Supplemental Content

Loading ...
Support Center